AtaiBeckley Inc. Overview
Pro stress-test →AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The company represents a merger between Atai Life Sciences and Beckley Psytech, combining their psychedelic-based drug development capabilities. Atai Life Sciences N.V. has surged >275% YTD, driven by promising psychedelic drug candidates targeting treatment-resistant depression and other mental health disorders.
Strategic Profile
Pro stress-test →AtaiBeckley Inc. is positioned favorably due to promising clinical data from its BPL-003 program, demonstrating improved MADRS scores and an increased remission rate after multiple doses, which indicates a robust potential for enhanced efficacy in treating treatment-resistant depression. The company estimates that BPL-003 could capture approximately 20% market share by 2035 based on its unique clinical profile and rapid time to market. The company's shares continue to trade on Nasdaq under the symbol 'ATAI.' It also reported that its common stock was added to the Nasdaq Biotechnology Index in December 2025.
Competitive Landscape
Pro stress-test →AtaiBeckley operates in the emerging clinical-stage psychedelics-for-psychiatry space competing against companies like MindMed (MNMD) and Compass Pathways (CMPS). The company differentiates through its diversified pipeline spanning multiple mental health indications and novel formulations. BPL-003's nasal spray format and rapid onset could offer market advantages over traditional oral therapies if clinical efficacy is sustained and regulatory approval achieved.
Industry Context
AtaiBeckley Inc. operates in Clinical-Stage Biopharmaceuticals / Psychedelic Psychiatry.
Key facts
Founded: 2018 · Headquarters: New York, US · Employees: 54 · Revenue: $0.75M (Q3 2025)